Immatics

Immatics Intangible Assets

The Intangible Assets of Immatics (IMTX) as of Nov 20, 2026 is 1.63 M EUR. In the previous year, Intangible Assets was 1.52 M EUR — a change of 6.96% (higher).

Intangible Assets

1.63 MEUR

YoY

6.96%

Last updated:

Intangible Assets of Immatics is 2024 1.63 M EUR. Intangible Assets of Immatics was 2023 1.52 M EUR. It decreases by 6.96% higher compared to the previous year.

The Immatics Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2019
1.00 M EUR
Jan 1, 2020
900,000.00 EUR
Jan 1, 2021
1.30 M EUR
Jan 1, 2022
1.60 M EUR
Jan 1, 2023
1.52 M EUR
Jan 1, 2024
1.63 M EUR
The Immatics Intangible Assets history
YEARIntangible AssetsYoY
1.63 MEUR+6.96%
1.52 MEUR-4.81%
1.60 MEUR+23.08%
1.30 MEUR+44.44%
900,000.00EUR-10.00%
1.00 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Immatics Stock analysis

What does Immatics do? Immatics NV develops T cell receptor-based immunotherapies for cancer treatment, focusing on solid tumors through Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). The company's pipeline includes eight therapeutic programs, with four in clinical trials: IMA201 (MAGEA4/8), IMA202 (MAGEA1), ACTolog IMA 101 (Multi-target pilot trial), and IMA203 (PRAME). Four programs are in preclinical development, such as IMA204 (COL6A3) and IMA401 (Cancer testis antigen). Immatics generates revenue through licensing agreements and potential future sales of its therapies, targeting pharmaceutical companies and research institutions seeking advanced cancer treatments. The company's clinical-stage therapies are designed to enable robust T-cell responses against cancer targets, with programs like IMA201 and IMA202 focused on solid tumors. IMA203 addresses both hematological and solid cancers, while preclinical programs like IMA401 and IMA402 target cancer testis antigens. Immatics partners with biopharmaceutical firms to advance its pipeline, leveraging its TCR technology platform to develop therapies for unmet medical needs in oncology. Immatics' revenue model relies on strategic partnerships and licensing deals with pharmaceutical companies, which fund clinical development and gain access to its proprietary TCR platform. The firm's focus on solid tumors and hematological cancers attracts interest from major biopharmaceutical players looking to expand their oncology portfolios. Through its eight therapeutic programs, Immatics aims to deliver innovative treatments that address high unmet medical needs in cancer therapy. Immatics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Immatics stock

Intangible Assets of Immatics is 1.63 M EUR in 2024.

Intangible Assets of Immatics changed from 1.52 M EUR to 1.63 M EUR, representing a 6.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Immatics since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Immatics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Immatics

All Key Metrics — Immatics